Ссылки
1. Gale E.A.M. Post-marketing studies of new insulins: sales or science? BMJ. 2012; 344: e3974.
2. Harris G., Pear R. Drug maker’s efforts to compete in lucrative insulin market are under scrutiny. New York Times. 2006 Jan 28.
3. Yudkin J.S. Post-marketing observational trials and catastrophic health expenditure. BMJ. 2012; 344: e3987.
4. Hawkes N. AstraZeneca must pay′52.5m fine for anticompetitive tactics, rules European court. BMJ. 2012; 345: e8396.
5. Edwards S.J., Lind T., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001; 15: 1729–36.
6. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
7. Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag 2007.
8. Tuffs A. Germany sees rise in post-marketing studies. BMJ. 2009; 339: b4199.
9. Hyde R. German doctors free to take cash from drug firms. Lancet. 2012; 380: 551.
10. Forgacs I., Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008; 336: 2–3.
11. McKay A.B. Overprescribing PPIs. BMJ. 2008; 336: 109.
12. Schwartz L.M., Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012; 344: e1086.
13. Lenzer J. FDA is criticised for licensing high dose donepezil. BMJ. 2011; 342: d3270.
14. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.
